Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors

Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors

Background Omacetaxine mepesuccinate is indicated in adults with chronic myeloid leukemia resistant and/or intolerant to ≥ 2 tyrosine kinase inhibitor treatments. This phase I study assessed the disposition, elimination, and safety of 14C-omacetaxine in patients with solid tumors. Methods The study...

Full description

Bibliographic Details
Main Authors: Nijenhuis, Cynthia M., Hellriegel, Edward, Beijnen, Jos H., Hershock, Diane, Huitema, Alwin D. R., Lucas, Luc, Mergui-Roelvink, Marja, Munteanu, Mihaela, Rabinovich-Guilatt, Laura, Robertson, Philmore, Rosing, Hilde, Spiegelstein, Ofer, Schellens, Jan H. M.
Format: Online
Language:English
Published: Springer US 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007276/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007276/

Similar Items